| Today's Top Story |  |  | | - FDA OKs Talon's leukemia drug Marqibo
Talon Therapeutics has gained FDA approval for Marqibo as a treatment for patients with Philadelphia chromosome negative acute lymphoblastic leukemia who do not respond to at least two prior therapies. Marqibo will be Talon's first product on the market. Reuters (8/9), Bloomberg (8/9)        |  |  | | How to turn money you already spend into points you can use:
The Business Gold Rewards Card from American Express OPEN, designed to earn Membership Rewards® points faster: 3X on airfare. 2X on advertising, gas & shipping. 1X on everything else. Use points to pay for travel, Amazon.com purchases, Facebook ads, and more.
LEARN MORE & APPLY | |  |  |  |
  | Health Care & Policy | | | | - Senator proposes $200M fund to help commercialize science
Sen. Kirsten Gillibrand, D-N.Y., has proposed a bill, called the America Innovates Act, intended to help companies, universities and research institutes bring scientific ideas to the market. The bill calls for the creation of a $200 million fund -- the American Innovation Bank -- to award grants and loans to universities and colleges, nonprofit research groups, private companies and individual researchers. The Record (Troy, N.Y.) (8/9), American City Business Journals/Albany, N.Y./The Business Review BizBlog (8/10) - Scientists aren't giving up on curing Alzheimer's disease
Recent failures of experimental Alzheimer's disease drugs may be disheartening, but researchers are not giving up the quest for a cure. Drugs under development include some that interrupt amyloid beta formation before it can accumulate in brain plaques. Researchers are also testing drugs in very early stages of the disease instead of after symptoms appear. National Public Radio/Shots blog (8/7) - Heart muscle cells work in sync with heart in animal study
 Human heart muscle cells grown from stem cells and injected into the damaged heart of a guinea pig improved contraction and worked in time with the heart to prevent arrhythmia. "This is the first demonstration that human heart muscle grafts can electrically stabilize the injured heart, and the first demonstration that they can couple and beat in sync," said cardiovascular biologist Dr. Charles E. Murry. The findings were published in the journal Nature. The Seattle Times (8/7) | Company & Financial News | | | |
| Food & Agriculture | | | | - Expert: Biotech foods don't harm humans and environment
Biotech foods don't pose risks to human health and the environment since they undergo extensive testing before being released on the market, according to Jonathan Padi Tetteh, a biotechnology expert in Ghana speaking at a meeting of the Open Forum on Agricultural Biotechnology in Africa. Most food imported into the country is biotech, "yet we eat and have no adverse effects," Tetteh said. Ghana News Agency (8/5) | Industrial & Environmental | | | | - Novozymes exec sees vast potential in waste-based fuels
The development of cellulosic biofuels from agricultural and forest waste will put to rest the food-vs.-fuel debate that hounds first-generation biofuels, said Lars Hansen, president of Novozymes North America. "If you take just 20% of the agricultural and forest residue available in Europe, which can sustainably be taken away from the fields, you can make half of Europe's gasoline demands," Larsen said. "The technology is in place. What we now need is for government policies to move in the right direction." BBC (8/8)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Eloquence is a painting of the thoughts."
--Blaise Pascal,
French mathematician, physicist, inventor and writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, August 09, 2012
- Wednesday, August 08, 2012
- Tuesday, August 07, 2012
- Monday, August 06, 2012
- Friday, August 03, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment